BOT Insider Trading (Botanix Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00
Botanix Pharmaceuticals Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
This Options Expert is Giving Everything Away!
From Tradewins | Ad
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you!
His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
Get your copy today!
Botanix Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2022 | Daniel Sharp | Insider | Issued | 5,000,000 | A$0.07 | A$355,000.00 | | |
| 2/21/2022 | Stewart Washer | Insider | Expiry | 4,000,000 | A$0.06 | A$232,000.00 | | |
| 6/30/2020 | Stewart Washer | Insider | Issued | 4,863,490 | A$0.04 | A$189,676.11 | | |
| 5/8/2020 | Michael Thurn | Insider | Expiry | 2,882,837 | A$0.05 | A$129,727.67 | | |
| 2/21/2020 | Stewart Washer | Insider | Expiry | 1,000,000 | A$0.09 | A$88,000.00 | | |
| 12/10/2019 | Michael Thurn | Insider | Exercise | 1,000,000 | A$0.09 | A$90,000.00 | | |
| 12/2/2019 | H. William Bosch | Insider | Exercise | 500,000 | A$0.07 | A$34,000.00 | | |
| 7/18/2019 | Michael Thurn | Insider | Issued | 5,000,000 | A$0.23 | A$1,125,000.00 | | |
What The White House Is NOT Telling You About The "Green Revolution."
From Investing Trends | Ad
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"
SEC Filings (Institutional Ownership Changes) for Botanix Pharmaceuticals (ASX:BOT)
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. Its product pipeline include BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase Ib clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in North Perth, Australia.
Read More on Botanix Pharmaceuticals
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
1,627,221 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Botanix Pharmaceuticals?
